LILRA2: A Protein Targeted for Small Molecules and Therapeutic Treatments

Target Name: LILRA2

NCBI ID: G11027

LILRA2

LILRA2: A Protein Targeted for Small Molecules and Therapeutic Treatments

LILRA2 (Leucine-rich repeat-containing adaptor protein 2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is characterized by the presence of a uniquerepeat domain in its extracellular domain, which is composed of 26 amino acids that are identical in sequence.

The repeat domain is responsible for LILRA2's unique structure and function. It is made up of a series of parallel repeated amino acids, which creates a 尾-sheet that is held together by ionic bonds. This structure is important for LILRA2's stability and functions as a protein.

LILRA2 is also known for its role in the immune response. It is a key regulator of the T cell response, specifically the development and function of CD8+ T cells. CD8+ T cells are a crucial part of the immune system, as they are responsible for killing infected cells and removing damaged tissue.

LILRA2 is also involved in the regulation of cell signaling pathways, including the production of reactive oxygen species (ROS) that can damage cells and contribute to the development of oxidative stress. This is important for the regulation of cell signaling pathways that are involved in the development and progression of diseases, such as cancer.

In addition to its role in the immune system and cell signaling pathways, LILRA2 is also a potential drug target. The repeat domain of LILRA2 makes it a promising target for small molecules, which can be used to inhibit its function and treat various diseases.

One approach to targeting LILRA2 is to use small molecules that are specific for the repeat domain. This can be done through a variety of methods, including site-directed mutagenesis, where small molecules are introduced at specific amino acid residues within the repeat domain.

Another approach to targeting LILRA2 is to use small molecules that can modulate its function by binding to specific interacting proteins. This can be done through a process called protein-protein interactions, which is the interaction between two proteins that results in the formation of a complex.

LILRA2 has also been shown to interact with several proteins, including the protein PDCD1 (Protamineurin 1), which is involved in the regulation of DNA replication and repair. The interaction between LILRA2 and PDCD1 has been shown to play a role in the regulation of CD8+ T cell development and function.

In conclusion, LILRA2 is a protein that is expressed in various tissues throughout the body and is involved in the immune response and cell signaling pathways. Its unique repeat domain and its role in the immune system make it a promising target for small molecules and a potential drug. Further research is needed to fully understand the function and potential of LILRA2.

Protein Name: Leukocyte Immunoglobulin Like Receptor A2

Functions: Part of the innate immune responses against microbial infection (PubMed:12529506, PubMed:27572839). Specifically recognizes a set of N-terminally truncated immunoglobulins that are produced via cleavage by proteases from a range of pathogenic bacteria and fungi, including L.pneumophila, M.hyorhinis, S.pneumoniae, S.aureus and C.albicans (PubMed:27572839). Recognizes epitopes that are in part in the variable region of the immunoglobulin light chains, but requires also the constant region for signaling (PubMed:27572839). Binds to a subset of cleaved IgM, IgG3 and IgG4 molecules, but does not bind cleaved IgA1 (PubMed:27572839). Binding of N-terminally truncated immunoglobulins mediates activation of neutrophils (PubMed:27572839). In monocytes, activation leads to the release of CSF2, CF3, IL6, CXCL8 and CCL3 and down-regulates responses to bacterial lipopolysaccharide (LPS), possibly via down-regulation of TLR4 expression and reduced signaling via TLR4 (PubMed:22479404). In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4 and leukotriene C4 (PubMed:12529506). Does not bind class I MHC antigens (PubMed:19230061)

The "LILRA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LILRA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets